Primary: To demonstrate the safety of autologous LSCs administered by intravenous infusion in patients with idiopathic pulmonary fibrosis. Secondary: To demonstrate the efficacy of autologous LSCs administered by intravenous infusion in patients with idiopathic pulmonary fibrosis.

This study is testing a new medication for patients who have group 1 PAH.

This registry will collect data on the strategies used to achieve a diagnosis of Idiopathic Pulmonary Fibrosis (IPF) and Chronic Fibrosing Interstitial Lung Disease with Progressive Phenotype (ILD) and the treatment and management efforts applied throughout study follow-up, clinical outcome events and patient reported outcome data. Blood samples will be collected periodically throughout the study for use in future research efforts. For participants with non-IPF, chronic fibrosing ILD with progressive phenotype, HRCT images will be collected throughout the study for use in future research efforts.

The purpose of this study is to evaluate a new test being developed by Tempus for patients with Non-Small Cell Lung Cancer (NSCLC). The goal of this new test is to predict the likelihood of a patient's cancer coming back after treatment, and to further explore changes in patient's tumors throughout treatment to see how they respond.

This is an exploratory study in cancer biomarker research, hoping to identify cell-signaling using DNA, in patients with SCLC.

This study will test how effectively changes in lung structure and function can be detected with a new inhaled gas combined with a MRI.

The virus that causes COVID-19 disease infects many people, but only some get sick. We want to understand how COVID affects the immune system and what makes severe COVID infections different from other diseases that cause hospitalization and breathing problems. We collect samples of blood, sputum, urine, and stool from patients in the hospital to learn how COVID affects cells and molecules of the immune system.

The primary objective of PATIENCE is to develop a standardized approach to the treatment of NTM in CF patients with a diagnosis of NTM disease. The secondary objectives are to: - Evaluate the feasibility and tolerability of a standardized treatment protocol for NTM disease - Evaluate effectiveness of a standardized NTM disease treatment protocol to serve as baseline/reference estimates of endpoints in clinical care and future therapeutic trials - Support biomarker development for markers of NTM treatment response through banking of clinical specimens and NTM isolates linked with outcomes data - Characterize clinical features of patients achieving treatment success compared to those unresponsive to treatment

The DNA that we can test from a nasal swab, can help us determine a patient's lung cancer risk. For patients with new lung nodules found on CT scans, we are offering this nasal swab test and collecting data on how physicians use test results to help assess risk and determine treatment strategies.

We don't know whether discharging patients with active delirium (aka confusion) home is appropriate. Returning patients to their home may lead to improvement and quicker delirium resolution. Alternately, it may be harmful as delirious patients may not be able to appropriately care for themselves in the home environment or follow discharge instructions. Consequently, they may get sicker, requiring hospital readmission or worse. Currently, there is no good way to assess delirium in the home setting. This greatly limits the ability to monitor and study this vulnerable population. The ability to perform in-home delirium assessments will prove invaluable to researchers investigating the a-propriateness of discharging actively delirious patients' home versus keeping them in the hospital until resolution of their delirium. Further, it will provide a method for clinicians to perform quick, remote delirium assessments of their patients.